Green Thumb Industries (GTBIF) Total Non-Current Liabilities (2019 - 2026)
Green Thumb Industries' (GTBIF) quarterly Total Non-Current Liabilities came in at $747.9 million in Q4 2024, down 0.75% YoY from $753.6 million in Q1 2024, and up 1.05% on a QoQ basis from $740.2 million in Q3 2024.
Green Thumb Industries (GTBIF) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Green Thumb Industries (GTBIF) has 6 years of Total Non-Current Liabilities data on file, last reported at $747.9 million in Q4 2024.
- Quarterly Total Non-Current Liabilities fell 0.75% year-over-year to $747.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $747.9 million (down 0.75% YoY) and the FY2024 annual result came in at $747.9 million, down 0.75% from the prior year.
- Total Non-Current Liabilities climbed to $747.9 million in Q4 2024, from $740.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $807.0 million in Q2 2023 to a low of $438213.0 in Q2 2021.
- A 5-year average of $342.2 million and a median of $956163.5 in 2020 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities plunged 32.45% — and 2022, when it surged 169964.33%.
- Tracing GTBIF's Total Non-Current Liabilities over 5 years: stood at $783000.0 in 2020, then retreated by 11.11% to $696000.0 in 2021, then slipped by 14.8% to $593000.0 in 2022, then surged by 126974.37% to $753.6 million in 2023, then retreated by 0.75% to $747.9 million in 2024.
- The last three Total Non-Current Liabilities figures came in at $747.9 million (Q4 2024), $740.2 million (Q3 2024), and $786.6 million (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 334.00 Mn |
| 10 | Green Thumb Industries | 1.65 Bn | 1.37 Bn | 137.87 Mn | 751.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 751.18 Mn |
| Dec 31, 2025 | 675.96 Mn |
| Dec 31, 2024 | 747.93 Mn |
| Sep 30, 2024 | 740.15 Mn |
| Jun 30, 2024 | 786.60 Mn |
| Dec 31, 2023 | 753.55 Mn |
| Sep 30, 2023 | 792.31 Mn |
| Jun 30, 2023 | 807.02 Mn |
| Mar 31, 2023 | 780.75 Mn |
| Dec 31, 2022 | 593,000.00 |
| Sep 30, 2022 | 622,000.00 |
| Jun 30, 2022 | 745.24 Mn |
| Mar 31, 2022 | 672,000.00 |
| Dec 31, 2021 | 696,000.00 |
| Jun 30, 2021 | 438,213.00 |
| Mar 31, 2021 | 762,865.00 |
| Dec 31, 2020 | 783,000.00 |
| Sep 30, 2020 | 473,136.00 |
| Jun 30, 2020 | 483,935.00 |
| Mar 31, 2020 | 1.13 Mn |